FDB (First Databank Inc), a provider of workflow-integrated drug knowledge for healthcare professionals, announced on Thursday the launch of its new gravimetric module, designed to help pharmacies improve the safety, accuracy, and efficiency of sterile compounding workflows for high-risk, high-cost medications.
The FDB Gravimetric Drug Density Module is a new clinical module contained within FDB MedKnowledge, the healthcare industry's most widely integrated drug database used by clinicians to make better medication decisions at the point of care. FDB MedKnowledge combines descriptive drug information, unique identifiers, and pricing data with an extensive array of clinical decision support modules to help pharmacists, physicians, nurses and other medical professionals avoid medication errors, prevent adverse drug events, reduce drug-related expenses, and improve the quality of patient care.
FDB's new Gravimetric Drug Density Module delivers normalised drug density data at the National Drug Code (NDC) level to support gravimetric verification during infusion medication preparation. By enabling clinical systems to calculate expected weights for compounded preparations and compare them against measured values, the module provides an additional layer of validation beyond traditional visual and volumetric checks. This capability is especially critical for high-risk, high-cost oncology therapies where minor deviations in dose can have significant clinical consequences.
Lilly acquires 4E Therapeutics to advance non-opioid chronic pain treatment
Minghui Pharmaceutical presents MHB018A Phase I/II results for thyroid eye disease at ENDO 2026
Kalohexis presents dual MC3R/MC4R activation data at ENDO 2026
Hillhurst Bio reports first subject dosed in Phase 2a trial of HBI-002 for Parkinson's disease
Lonza and Antharis Therapeutics enter target-specific licence agreement
Inhibrx's ozekibart BLA accepted by FDA for chondrosarcoma treatment
Sensei Biotherapeutics changes name to Faeth Therapeutics
Bayer receives FDA approval for AMBELVIST MRI contrast agent